SIHUAN PHARM News

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 2 04:04 ET

SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 28 00:17 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL OBTAINED CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FROM NMPA FOR EXCLUSIVELY DISTRIBUTED DUAL WAVE RF TREATMENT DEVICE SYLFIRM X

Mar 25 00:00 ET

SIHUAN PHARM: NOTICE OF BOARD MEETING

Mar 18 04:31 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 1 03:02 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - PARTICIPATION IN THE CONSORTIUM WHO WAS SELECTED AS THE PRE-RESTRUCTURING INVESTOR FOR THE BANKRUPTCY AND RESTRUCTURING PROJECT OF JI YAO HOLDING

Feb 7 06:49 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 1 03:03 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-HUISHENG BIOPHARMACEUTICAL''S SGLT-2 INHIBITOR INNOVATIVE DRUG PROLINE JANAGLIFLOZIN TABLETS OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

Jan 22 17:06 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - FOUR NON-PVC SOLID-LIQUID DOUBLE CHAMBER BAG PRODUCTS, DEVELOPED BY SIHUAN PHARMACEUTICAL''S ASSOCIATE COMPANY BEIJING RUIYE, ARE NEWLY INCLUDED IN NRDL 2023

Jan 9 07:54 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-THREE INSULIN ASPART PRODUCTS DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

Jan 7 23:00 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 3 03:00 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023

Dec 1, 2023 03:02 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023

Nov 1, 2023 04:00 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE INJECTION, DEVELOPED BY HUISHENG BIOPHARMACEUTICAL, APPROVED BY NMPA

Oct 24, 2023 18:00 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB''S MONOTHERAPY, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM FOR THE TREATMENT OF ADVANCED BREAST CANCER, WAS ACCEPTED BY NMPA

Oct 16, 2023 18:03 ET

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023

Oct 3, 2023 04:02 ET

SIHUAN PHARM: Notification Letter and Request Form to Non-registered Holder

Sep 26, 2023 04:31 ET

SIHUAN PHARM: Notification Letter and Change Request Form to Registered Shareholder

Sep 26, 2023 04:30 ET

SIHUAN PHARM: Interim Report 2023

Sep 26, 2023 04:30 ET

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - THE NDA OF CLASS 1 INNOVATIVE DRUG BIROCICLIB TABLETS, INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARMACEUTICAL, ACCEPTED BY NMPA

Sep 4, 2023 18:05 ET